Antibody-based targeted alpha therapy for ovarian cancer
Official title: Antibody-based prertargeted alpha particle therapy for ovarian cancer
Funded at Viewpoint Molecular Targeting, INC. · NIH-11247612 · Data updated 2026-11-12
A new antibody-guided treatment using alpha radiation is being developed for women with metastatic high-grade serous ovarian cancer to improve outcomes after standard therapies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Viewpoint Molecular Targeting, INC. NIH-funded |
| Lab location | 1 site (Coralville, UNITED STATES) |
| Project start | June 5, 2024 |
| Project end | June 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $1,006,109 |
| NIH project number | 4R42CA287696-02 |
| Project ID | NIH-11247612 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are patients with metastatic/high-risk high-grade serous ovarian cancer expressing TAG72 and who have progressed after standard treatments.
✕Less likely to help
Patients whose tumors do not express TAG72 or who cannot tolerate the treatment may not benefit.
What this research studies
This project aims to combine a novel pretargeting system with alpha-particle therapy to target TAG72-positive ovarian cancer cells. Researchers will use image-guided delivery to concentrate treatment in tumors while reducing exposure to healthy tissues. The work involves collaboration with Viewpoint Molecular Targeting to develop and potentially commercialize the therapy for patients who relapse after frontline treatment.
Why it matters
Potential benefit: If successful, patients with metastatic ovarian cancer could have more effective tumor control and potentially longer survival with a targeted, image-guided therapy.
How similar studies have gone: Alpha-particle therapies have shown promise in other cancers, but this exact pretargeting approach for ovarian cancer is relatively novel and under early development.
Where this research is happening
-
Viewpoint Molecular Targeting, INC.
Coralville, United States Active
Researchers
- Principal investigator: Schultz, Michael King — Viewpoint Molecular Targeting, INC.
- Study coordinator: Schultz, Michael King
Related research
Other NIH-funded projects on the same topics.
-
Understanding the experience of ovarian cancer after diagnosis to improve survivorship
This NIH grant funds a mixed-methods study to better understand physical and emotional challenges faced by ovarian cancer survivors and how supportive care can help them live better after diagnosis.
-
Targeting quiescent ovarian cancer cells to overcome chemotherapy resistance
A study focusing on why some ovarian cancer cells pause dividing and resist chemotherapy, with the goal of finding new treatment targets for relapsed disease.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
-
Integrated framework to validate and quantify proteoforms in patient-derived ovarian cancer cells
A collaboration will combine advanced top-down proteomics with a new computational method to precisely identify and measure intact proteoforms in tiny samples from ovarian cancer cells.
-
Overcoming platinum resistance in ovarian cancer: finding biomarkers and new targets
Researchers are looking for new biomarkers and targets to help prevent or overcome platinum resistance in high‑risk ovarian cancer so patients have better chances at long-term control.
-
Alternative NF-kB activation after chemotherapy in ovarian cancer
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.